CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Kuros Biosciences AG is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Kuros Biosciences AG
Wagistrasse 25
Phone: +41 447334747p:+41 447334747 SCHLIEREN, 8952  Switzerland Ticker: KURNKURN
Business Summary
Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board of Directors ClemensVan Blitterswijk 67 6/14/2018 6/1/2017
Chief Executive Officer, Member of the Executive Board ChrisFair 52 10/1/2023 4/19/2021
Chief Financial Officer, Member of the Executive Board DanielGeiger 53 5/1/2023 5/1/2023
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Kuros Biosciences BV Professor Bonkhorstlaan 10 Bilthoven Netherlands

Business Names
Business Name
0RHR
CYTN
Cytos Biotechnology
9 additional Business Names available in full report.

General Information
Number of Employees: 80 (As of 12/31/2023)
Outstanding Shares: 36,848,805 (As of 4/8/2024)
Shareholders: 1,500
Stock Exchange: SWF
Fax Number: +41 447334740


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024